NovoCure Limited NVCR
11.83 USD +0.11 (+0.94%)
At closeNov 13, 2026, 4:00 PM EST
11.83 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
11.44 Day range 11.88
9.82 52-week range 21.45
- YTD
- -8.51%
- 1 year
- +3.95%
News
benzinga.com NovoCure Announces Publication Of Data Analysis From Phase 3 PANOVA-3 Trial Novocure (NASDAQ:NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields)…
businesswire.com JAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields for Pancreatic Cancer BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that JAMA Network Open published the results of the prespecified secondary analysis of data from the Phase 3 PANOVA-3 trial…
benzinga.com Ladenburg Thalmann Maintains Buy on NovoCure, Raises Price Target to $31 Ladenburg Thalmann analyst Kevin DeGeeter maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $27 to $31.
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 13.9% to $2.2 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Longeveron (NASDAQ:LGVN) stock…
fool.com FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors. Mya is an investigational product in the Optune line. These wearable devices generate electric fields that disrupt cell division, ideally preventing the spread of cancer.- benzinga.com Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19 Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target from $20 to $19.
benzinga.com Novocure Stock Slips After FDA Rejects Its Cancer Treatment Device Novocure receives an FDA Not Approvable Letter for Optune Mya in NSCLC brain metastases, citing unclear clinical benefit while finding no safety issues.- benzinga.com Novocure Receives Not Approvable Letter From FDA In Response To PMA Application For Optune Mya For Treatment Of Adult Patients With Brain Metastases From Non-Small Cell Lung Cancer Following Stereotactic Radiation Novocure (NASDAQ:NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket Approval (PMA) application for Optune…
businesswire.com Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has received a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) in response to its Premarket…
benzinga.com Wells Fargo Maintains Equal-Weight on NovoCure, Lowers Price Target to $15 Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Equal-Weight and lowers the price target from $20 to $15.
benzinga.com Evercore ISI Group Maintains Outperform on NovoCure, Lowers Price Target to $20 Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a Outperform and lowers the price target from $23 to $20.
benzinga.com NovoCure Q3 2026 Earnings Call Transcript NovoCure (NASDAQ:NVCR) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com NovoCure Q3 EPS $(0.09) Beats $(0.24) Estimate, Sales $193.399M Beat $182.233M Estimate NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.24) by 62.5 percent. This is a 72.73 percent increase over losses of $(0.33) per…
benzinga.com NovoCure Raises FY2026 Sales Guidance from $710.000M-$725.000M to $736.000M-$743.000M vs $725.814M Est NovoCure (NASDAQ:NVCR) raises FY2026 sales outlook from $710.000 million-$725.000 million to $736.000 million-$743.000 million vs $725.814 million estimate.
benzinga.com Japan’s Ministry Of Health, Labour And Welfare Approves Novocure's Optune Pax To Treat Adults With Unresectable Locally Advanced Pancreatic Cancer Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally…
benzinga.com Crude Oil Rises Sharply; T-Mobile Shares Fall Following Q2 Results US stocks lower, Dow down 0.92%, NASDAQ 2.03% decline. T-Mobile stock falls 5%. NVE Corp up 38%, Novocure up 25%, Cleveland-Cliffs up 19%
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regular session. The market value of their outstanding shares is at $1.8 billion. The company's, Q2 earnings…
benzinga.com Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday U.S. stocks were down as Dow Jones fell 450 points on Thursday. Lockheed Martin (LMT) shares rose 11.4% on better-than-expected results. Other big gainers were NVE Corp (NVEC), Gibo Holdings Ltd…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Niki BioSolutions (NASDAQ:NIKI) stock moved upwards by 44.7% to $13.01 during Thursday's pre-market session. The company's market cap stands at $73.2 million. Zhengye Biotechnology…
benzinga.com Earnings Scheduled For July 23, 2026 Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Crude Oil Down 2%; Accenture Shares Fall After Q3 Results U.S. stocks traded higher on Thursday with the S&P 500 gaining 1% while tech shares surged 2.3%. Accenture stock tumbled 15% after weaker outlook.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session 
benzinga.com Caterpillar Posts Upbeat Q1 Results, Joins Garrett Motion, Wesco International, TTM Technologies And Other Big Stocks Moving Higher On Thursday US stocks mixed, Dow up 400 pts. Caterpillar, Bandwidth, Everspin, Vistance, IMPINJ, Novocure, Viavi, Garrett, Hertz, Ranpak all gain in Q1.- benzinga.com Earnings Scheduled For April 30, 2026
benzinga.com NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer NovoCure shares rise after PANOVA-4 data show higher disease control and survival signals in metastatic pancreatic cancer.- benzinga.com Earnings Scheduled For February 26, 2026
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Acadia Healthcare Posts Upbeat Q4 Earnings, Joins Circle Internet, Resideo Technologies And Other Big Stocks Moving Higher On Wednesday 
benzinga.com S&P 500 Falls Over 1%; American Electric Power Shares Gain After Upbeat Earnings - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com HubSpot, Crocs, Zebra Technologies, Trinity Industries And Other Big Stocks Moving Higher On Thursday - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why Fastly Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket 
benzinga.com Earnings Scheduled For October 30, 2025 - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Earnings Scheduled For July 24, 2025
benzinga.com This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Earnings Scheduled For April 24, 2025
benzinga.com Earnings Scheduled For February 27, 2025 
benzinga.com Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio? These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.- benzinga.com SoundHound, Asana And Victorias Secret Are Among Top 10 Mid Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio? Top performing mid-cap stocks last week: NBIS, SOUN, BTDR, ASAN, JANX, NVCR, KC, VSCO, ZETA, FIVE. Analysts raise price forecasts for these stocks.
- benzinga.com XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
- benzinga.com Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
benzinga.com PayPal Posts Upbeat Earnings, Joins Sprouts Farmers Market, Stanley Black & Decker, Phillips 66 And Other Big Stocks Moving Higher On Tuesday - benzinga.com Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
- benzinga.com Market-Moving News for March 27th IBIO: 119% | IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases. DRCT: -49% | Direct Digital Holdings
benzinga.com Earnings Scheduled For February 22, 2024 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.